Acute Myeloid Leukemia | CHOP Research Institute
 

Acute Myeloid Leukemia

Scientists Target FLT3 Protein in New Approach for High-risk Childhood Leukemias

Published on
Sep 8, 2023
in Cornerstone Blog
Immunotherapy Target in Two High-risk Childhood Leukemias
Sarah K. Tasian, MD, received a $1 million grant to further her research into a novel immunotherapy for high-risk pediatric leukemias.

In the News: FLT3 CAR T-cell Immunotherapy, Lymphatic Conference, Cellicon Valley, Pediatric Heatstroke

Published on
Jul 7, 2023
in Cornerstone Blog
In the News: Lymphatic Conference and Cellicon Valley Highlights
See highlights from the Third Annual Lymphatic Disorder Conference and Cellicon Valley ’23, and more in this week’s research news roundup.

Snapshot Science: Do RAB Proteins Play a Role in Development of Acute Myeloid Leukemia?

Published on
Jun 22, 2023
in Cornerstone Blog
Protein Linked to AML
Wei Tong, PhD, and colleagues found a protein interaction that appears to be a driver of hematologic malignancies.

In the News: Outstanding Science Award, Highly Cited Researcher, STAT Wunderkinds

Published on
Dec 9, 2022
in Cornerstone Blog
In the News
This week's news roundup features an outstanding science award, Highly Cited Researchers, and STAT Wunderkinds, along with new research about cancer risk with birth defects, epilepsy, and acute myeloid leukemia.

Where Discovery Leads: Taking CAR T-Cell Therapy to Solid Tumors and Beyond

Published on
Sep 19, 2022
in Cornerstone Blog
Where Discovery Leads: CAR T-Cell Therapy Research
CHOP physician-scientists discuss their CAR T-cell therapy research for childhood cancers in Where Discovery Leads.

AAML1921; Bosutinib for Chronic Myeloid Leukemia

The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).

Snapshot Science: How Does the Overexpression of MN1 Cause Acute Myeloid Leukemia?

Published on
May 19, 2021
in Cornerstone Blog
How the Overexpression of MN1 Causes Acute Myeloid Leukemia
CHOP Researchers find the novel mechanistic link by which MNI causes acute myeloid leukemia.

Tasian Laboratory

Tasian Lab

Research in the Tasian Laboratory focuses on the bench-to-bedside investigation of precision medicine therapies for high-risk childhood leukemias.

CD33 CART AML

CD33 CART AML

This phase 1/2 study will determine the safety, feasibility, and efficacy of CD33 CART cells following lymphodepleting chemotherapy in patients with acute myeloid leukemia (AML).

Aplenc Laboratory

Aplenc Lab

The Aplenc Lab investigates ways to improve the outcomes of children with cancer, particularly acute myeloid leukemia, through translational studies, patient-centered outcomes research, and with clinical epidemiology studies.